Cullen Frost Bankers Inc. purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 1st quarter, HoldingsChannel reports. The institutional investor purchased 654 shares of the specialty pharmaceutical company’s stock, valued at approximately $93,000.

Several other institutional investors also recently added to or reduced their stakes in JAZZ. JPMorgan Chase & Co. boosted its holdings in shares of Jazz Pharmaceuticals by 3.0% in the third quarter. JPMorgan Chase & Co. now owns 1,912,173 shares of the specialty pharmaceutical company’s stock valued at $321,494,000 after buying an additional 56,291 shares during the period. Martingale Asset Management L P boosted its holdings in shares of Jazz Pharmaceuticals by 10,786.8% in the third quarter. Martingale Asset Management L P now owns 174,516 shares of the specialty pharmaceutical company’s stock valued at $29,342,000 after buying an additional 172,913 shares during the period. Macquarie Group Ltd. boosted its holdings in shares of Jazz Pharmaceuticals by 115.4% in the third quarter. Macquarie Group Ltd. now owns 2,800 shares of the specialty pharmaceutical company’s stock valued at $471,000 after buying an additional 1,500 shares during the period. Teachers Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 0.6% in the third quarter. Teachers Advisors LLC now owns 690,409 shares of the specialty pharmaceutical company’s stock valued at $116,078,000 after buying an additional 4,217 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its holdings in Jazz Pharmaceuticals by 1.2% during the third quarter. TIAA CREF Investment Management LLC now owns 1,332,172 shares of the specialty pharmaceutical company’s stock worth $223,978,000 after purchasing an additional 15,607 shares during the last quarter. Institutional investors own 94.25% of the company’s stock.

Several brokerages recently commented on JAZZ. Zacks Investment Research cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday. BidaskClub cut shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, April 19th. ValuEngine cut shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, April 18th. Mizuho restated a “hold” rating and set a $147.00 target price (up previously from $137.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, March 27th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $185.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, March 26th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $182.71.

Shares of JAZZ stock opened at $132.81 on Tuesday. The firm has a market capitalization of $7.51 billion, a price-to-earnings ratio of 10.85, a PEG ratio of 1.08 and a beta of 1.16. The company has a quick ratio of 3.42, a current ratio of 3.57 and a debt-to-equity ratio of 0.57. Jazz Pharmaceuticals PLC has a one year low of $113.52 and a one year high of $184.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $3.27 EPS for the quarter, beating analysts’ consensus estimates of $2.66 by $0.61. The firm had revenue of $476.46 million during the quarter, compared to analysts’ expectations of $459.48 million. Jazz Pharmaceuticals had a net margin of 23.64% and a return on equity of 26.20%. The company’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.95 earnings per share. As a group, equities research analysts predict that Jazz Pharmaceuticals PLC will post 13.19 earnings per share for the current fiscal year.

In other Jazz Pharmaceuticals news, CFO Matthew P. Young sold 1,152 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $135.41, for a total value of $155,992.32. Following the completion of the sale, the chief financial officer now owns 38,700 shares in the company, valued at $5,240,367. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Suzanne Sawochka Hooper sold 6,666 shares of the stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $140.00, for a total transaction of $933,240.00. Following the completion of the sale, the executive vice president now owns 40,401 shares of the company’s stock, valued at approximately $5,656,140. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,668 shares of company stock valued at $1,606,567. Corporate insiders own 3.90% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Cullen Frost Bankers Inc. Purchases Shares of 654 Jazz Pharmaceuticals PLC (JAZZ)” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/cullen-frost-bankers-inc-purchases-shares-of-654-jazz-pharmaceuticals-plc-jazz/3000563.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: What is a Tariff?

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.